| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
I evaluated the relationship between epithelium-Mesenchymal transition and features of hepatic cancer stem cells. Moreover, I identified new therapy based on a pattern of stemness surface markers. In epithelial-like HCC cases, highly expression of EpCAM or CD133, or activation of HDAC1 pathway indicated poor prognosis. While, in mesenchymal-like HCC cases, highly expression of CD56 or CD90, or activation of DNMT1 or DNMT3b pathways were poor prognostic marker. HDAC1 inhibitor suppressed tumor proliferation and invasion in Epithelial-like HCC cells. On the other hand, DNMT inhibitor showed the anti-tumor effect in Mesenchymal-like HCC cells. In Epithelial-like HCC cells, combination DNA-effected anti-cancer drugs and HDAC inhibitor indicated synergistic effect in the suppression of tumor proliferation and invasion. This combination therapy may be new therapy for Epithelial-like HCC cases.
|
